Abstract
Purpose
To investigate the effects and safety of gonadotropin releasing hormone analogue (GnRH-a) as an addition to progesterone luteal support in women who underwent in vitro fertilization/intracytoplasmic sperm injection-embryo transfer (IVF/ICSI-ET) and achieved a clinical pregnancy.
Methods
A retrospective analysis was conducted on 214 patients who underwent IVF/ICSI-ET procedures with standard long mid-luteal protocol, of which 123 received GnRH-a-free protocol and 91 received GnRH-a-added protocol. The patients’ pregnancy and delivery course, and their neonates’ status at birth and growth/development after birth were statistically compared.
Results
There was no significant difference between both study groups regarding embryo risks and maternal complications during early pregnancy. as well as fetal risks during the middle and late stages and neonate risks during birth, except that the twin pregnancies of the GnRH-a-added group had a considerably greater male/female ratio, and a significantly higher rate of premature delivery and low birth weight than those of the GnRH-a-free group. In addition, there was no significant difference in neonate risks within 2 years after birth between both cohorts.
Conclusion
With precautions taken to control the number of implanted embryos and reduce the incidence of twinning pregnancy, the addition of GnRH-a to luteal support is relatively safe and effective.
Similar content being viewed by others
References
Raju GA, Chavan R, Deenadayal M, Gunasheela D, Gutgutia R, Haripriya G, Govindarajan M, Patel NH, Patki AS (2013) Luteinizing hormone and follicle stimulating hormone synergy: a review of role in controlled ovarian hyper-stimulation. J Hum Reprod Sci 6:227–234
Fatemi HM (2009) The luteal phase after 3 decades of IVF: what do we know? Reprod Biomed Online 19(Suppl 4):4331
Connell MT, Szatkowski JM, Terry N, DeCherney AH, Propst AM, Hill MJ (2015) Timing luteal support in assisted reproductive technology: a systematic review. Fertil Steril 103(939–946):e933
Ciampaglia W, Cognigni GE (2015) Clinical use of progesterone in infertility and assisted reproduction. Acta Obstet Gynecol Scand 94(Suppl 161):17–27
van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M (2015) Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 7:CD009154
Lahlou N (2005) Pharmacocinétique et pharmacodynamique de la triptoréline. Ann Urol 39(Suppl 3):S78–S84
Chen L, He HX, Sun XD, Zhao J, Liu LH, Huang WQ, Zhang RQ (2004) Expression of gonadotropin-releasing hormone receptor and effect of gonadotropin-releasing hormone analogue on proliferation of cultured gastric smooth muscle cells of rats. World J Gastroenterol 10:1780–1784
Breyer P, Haider A, Pescovitz OH (1993) Gonadotropin-releasing hormone agonists in the treatment of girls with central precocious puberty. Clin Obstet Gynecol 36:764–772
Balasch J, Martinez F, Jove I, Cabre L, Coroleu B, Barri PN, Vanrell JA (1993) Inadvertent gonadotrophin-releasing hormone agonist (GnRHa) administration in the luteal phase may improve fecundity in in-vitro fertilization patients. Hum Reprod 8:1148–1151
Kyrou D, Kolibianakis EM, Fatemi HM, Tarlatzi TB, Devroey P, Tarlatzis BC (2011) Increased live birth rates with GnRH agonist addition for luteal support in ICSI/IVF cycles: a systematic review and meta-analysis. Hum Reprod Update 17:734–740
Yildiz GA, Sukur YE, Ates C, Aytac R (2014) The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 182:66–70
Kung HF, Chen MJ, Guua HF, Chen YF, Yi YC, Yen-Ping Ho J, Chou MM (2014) Luteal phase support with decapeptyl improves pregnancy outcomes in intracytoplasmic sperm injection with higher basal follicle-stimulating hormone or lower mature oocytes. J Chin Med Assoc 77:524–530
Zafardoust S, Jeddi-Tehrani M, Akhondi MM, Sadeghi MR, Kamali K, Mokhtar S, Badehnoosh B, Arjmand-Teymouri F, Fatemi F, Mohammadzadeh A (2015) Effect of administration of single dose GnRH agonist in luteal phase on outcome of ICSI-ET cycles in women with previous history of IVF/ICSI failure: a randomized controlled trial. J Reprod Infertil 16:96–101
Sahin S, Ozay A, Ergin E, Turkgeldi L, Kurum E, Ozornek H (2015) The risk of ectopic pregnancy following GnRH agonist triggering compared with hCG triggering in GnRH antagonist IVF cycles. Arch Gynecol Obstet 291:185–191
de Onis M, Garza C, Onyango AW, Borghi E (2007) Comparison of the WHO child growth standards and the CDC 2000 growth charts. J Nutr 137:144–148
Kada S, Nygaard HA, Geitung JT, Mukesh BN, Naik M, Wold G, Soevik DH (2007) Quality and appropriateness of referrals for dementia patients. Qual Prim Care 15:53–57
Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C (2006) Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles. Hum Reprod 21:2572–2579
Ruan HC, Zhu XM, Luo Q, Liu AX, Qian YL, Zhou CY, Jin F, Huang HF, Sheng JZ (2006) Ovarian stimulation with GnRH agonist, but not GnRH antagonist, partially restores the expression of endometrial integrin beta3 and leukaemia-inhibitory factor and improves uterine receptivity in mice. Hum Reprod 21:2521–2529
Wong KH, Simon JA (2004) In vitro effect of gonadotropin-releasing hormone agonist on natural killer cell cytolysis in women with and without endometriosis. Am J Obstet Gynecol 190:44–49
Cahill D (1998) Risks of GnRH agonist administration in early pregnancy. In: Filicori M, Flamigni C (eds) Ovulation induction: update ‘98. The Parthenon Publishing Group, London, pp 97–105
Simsek E, Kilicdag EB, Aytac PC, Coban G, Simsek SY, Cok T, Haydardedeoglu B (2015) Addition of gonadotropin releasing hormone agonist for luteal phase support in in-vitro fertilization: an analysis of 2739 cycles. J Turk Ger Gynecol Assoc 16:96–101
Nugent D, Vandekerckhove P, Hughes E, Arnot M, Lilford R (2000) Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 4:CD000410
Lorusso F, Depalo R, Selvaggi L (2004) Relationship between gonadotropin releasing hormone agonist dosage and in vitro fertilization outcome. Gynecol Endocrinol 18:69–73
Walker LM, Tran S, Robinson JW (2013) Luteinizing hormone–releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects. Clin Genitourin Cancer 11:375–384
Author contribution
WZ: Project management, Data Collection, Manuscript writing. YZ: Data collection, Data analysis. YP: Manuscript writing. FX: Data analysis.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study was funded by the Maternal and Child Health Research Program of Jiangsu Province (No. F201547).
Conflict of interest
All authors declare that they have no conflict of interest regarding this study.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was waived due to the retrospective nature of this study.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Zhou, W., Zhuang, Y., Pan, Y. et al. Effects and safety of GnRH-a as a luteal support in women undertaking assisted reproductive technology procedures: follow-up results for pregnancy, delivery, and neonates. Arch Gynecol Obstet 295, 1269–1275 (2017). https://doi.org/10.1007/s00404-017-4353-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-017-4353-5